A Different Approach To Corporate Venture: An Interview With AbbVie Ventures' Scott Brun
AbbVie Ventures is young, but the group was set up with specific goals: to invest specifically in tune with AbbVie's therapeutic focus areas and not to focus purely on return on investment.
You may also be interested in...
The tax reform windfall makes an already strong fourth quarter and full year 2017 financial report more impressive for AbbVie, which reported continuing growth for Humira and Imbruvica, and a big uptick in HCV.
AbbVie agreed to pay $205m up front to biotech start-up Alector to research a portfolio of antibody targets to treat Alzheimer's and other neurodegenerative diseases by harnessing the immune system.
The proprietary pharmaceuticals business – slated to break off from Abbott on Jan. 1, 2013 – will generate sales of around $18 billion, have a cash balance of $7 billion and an annual R&D spend of around 14% of sales, about $2.52 billion in 2013.